股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | 本月底法定/註冊股本總 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | | --- | --- | | 已符合適用的公眾持股量要求（見下方） | ✔ | | 未符合適用的公眾持股量要求（見下方） | | | 根據《主板上市規則》第13.32B條或第19A.28B條 / 《GEM上市規則》第17.37B條或第25.21B條（視情況而定）所載的有關股份類別的最低公眾持股量要求為： | | | 適用的公眾持股量門檻 初始指定門檻 - 上市股份所屬類別的已發行股份總數(不包括庫存股份)的25% | | | 額外信息 | | I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 HKD | | | 120,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 480,000,000 | HKD | | 0.25 HKD | | | 120,000,000 | 本月底法定/註冊股本 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： HKD 120,000,000 FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 HKD | | | 120,000,000 | | 增加 / 減少 (-) | | | ...

公司名稱: 保集健康控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | 本月底法定/註冊股本總 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 480,000,000 | HKD | | 0.25 | HKD | | 120,000,000 | 本月底法定/註冊股本總 ...

第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 保集健康控股有限公司 呈交日期: 2026年1月20日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01246 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 480,000,000 | HKD | | 0.25 HKD | | | 120,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 480,000,000 | HKD | | 0.25 HKD | | | 120, ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失 承 擔 任 何 責 任。 Boill Healthcare Holdings Limited 保集健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1246） (1)董 事 會 成 員 變 動； (2)辭 任 及 罷 免 董 事； (3)變 更 公 司 秘 書 及 授 權 代 表；及 (4)更改主要營業地點 董事會成員變動 董 事 會 欣 然 宣 佈：(1)何 先 生 已 獲 委 任 為 執 行 董 事；(2)鄧博士已獲委任 為 非 執 行 董 事；及(3)麥 女 士、(4)陳先生及(5)梁先生已獲委任為獨立非 執 行 董 事，自 二 零 二 四 年 十 二 月 三 十 日 起 生 效。 自 同 日 起，裘 先 生、崔 先 生 及 易 先 生 各 自 辭 任 董 事 及 不 再 擔 任 董 事 會 轄 下 委 員 會 之 主 席 或 成 員。自 二 零 ...

Financial Performance - For the fiscal year ending March 31, 2024, the total revenue was HKD 285,204,000, a decrease of 18.1% compared to HKD 348,271,000 in the previous year[2] - The gross profit for the same period was HKD 11,655,000, significantly improved from HKD 110 in the previous year[2] - The loss before tax increased to HKD 275,502,000, compared to a loss of HKD 224,636,000 in the prior year, reflecting a deterioration of 22.6%[3] - The total comprehensive loss for the year was HKD 351,771,000, down from HKD 575,808,000 in the previous year, indicating a 38.9% improvement[3] - The company reported a net loss attributable to owners of the company of HKD 197,262,000, compared to HKD 238,873,000 in the previous year, reflecting a 17.4% improvement[5] - The company reported a loss attributable to owners of the company of HKD 118,640,000 for the year ended March 31, 2024, compared to a loss of HKD 223,615,000 for the previous year[54] - The net loss for fiscal year 2024 was approximately HKD 283.1 million, a decrease of about HKD 244.5 million from HKD 527.6 million in fiscal year 2023[95] Assets and Liabilities - The company's total assets decreased to HKD 1,300,167,000 from HKD 2,416,217,000, a decline of 46.1% year-over-year[7] - Current liabilities exceeded current assets by HKD 1,056,099,000, compared to a surplus of HKD 44,212,000 in the previous year[8] - The company had cash and cash equivalents of HKD 469,000, a significant decrease from HKD 40,638,000 in the previous year[7] - The company’s borrowings amounted to HKD 842,175,000, with a substantial portion classified as current liabilities due to covenant breaches[11] - As of March 31, 2024, the group's net current liabilities were approximately HKD 1,056.1 million, compared to a net current asset of approximately HKD 44.2 million as of March 31, 2023[105] - The group's net liabilities are approximately HKD 332,903,000 respectively, indicating significant uncertainty regarding the group's ability to continue as a going concern[129] Revenue Sources - For the fiscal year ending March 31, 2024, the revenue from property sales was HKD 285,005 thousand, an increase from HKD 169,481 thousand in the previous year, representing a growth of 68.3%[32] - The revenue from construction material sales was HKD 178,637 thousand in the fiscal year ending March 31, 2023, while there was no revenue reported for the fiscal year ending March 31, 2024[32] - The total revenue from continuous operations for the fiscal year ending March 31, 2024, was HKD 285,204 thousand, down from HKD 348,271 thousand in the previous year, indicating a decrease of 18.1%[32] Operational Changes - The company has focused its operations on property development following the sale of its wellness resort business, which is now classified as discontinued operations[24] - The company agreed to sell its wellness resort in Shanghai for a cash consideration of RMB 1,185,000,000 (approximately HKD 1,356,519,000) on November 25, 2022[41] - The company completed the construction of the Yangzhong project, generating revenue of approximately HKD 285.2 million from the sale of 343 apartments with a total construction area of about 42,603 square meters[79] Financing and Liquidity - The group plans to actively negotiate with investors and banks for new financing and to extend bank loan agreements to manage its financial obligations[16] - The group is facing significant uncertainty regarding its ability to continue as a going concern due to the inability to recover loans totaling RMB 135.0 million (equivalent to HKD 146.3 million) from Bao Ji Holdings[14] - The group has a bank balance of approximately HKD 14.9 million that has been frozen due to legal claims amounting to RMB 41.5 million (equivalent to HKD 45.0 million)[12] - The group continues to sell completed properties and pre-sell development properties to increase liquidity[109] Legal and Compliance Issues - The group faces several legal claims primarily related to construction contract disputes in its property development projects[113] - The independent auditor's report states that no opinion is expressed on the consolidated financial statements due to insufficient appropriate audit evidence[128] - The audit committee has critically reviewed the basis for the disclaimer of opinion and acknowledges the management's view on the group's ability to continue operating[133] Future Outlook - The company anticipates that the real estate industry will continue to face structural adjustments and challenges in the upcoming fiscal year 2025[96] - The group plans to focus on the biopharmaceutical and medical device industry parks, establishing a comprehensive development strategy starting in 2023[100] - The group anticipates challenges in its existing industrial park development model by 2025, necessitating a strategic upgrade[99]

Financial Performance - For the six months ended September 30, 2023, the company reported revenue of HK$274,659,000, a slight increase of 2.4% compared to HK$268,047,000 for the same period in 2022[11]. - The gross profit for the same period was HK$12,114,000, up from HK$11,573,000, reflecting a gross margin improvement[11]. - The loss before tax decreased to HK$18,548,000 from HK$23,911,000, indicating a reduction in operational losses[11]. - The total comprehensive income for the period was a loss of HK$45,762,000, compared to a loss of HK$184,815,000 in the previous year, showing significant improvement[15]. - The company incurred a loss for the period from continuing operations of HK$23,211,000, down from HK$28,457,000 in the prior year[11]. - Total comprehensive income attributable to owners of the company for the six months ended September 30, 2023, was a loss of HK$34,584,000, compared to a profit of HK$55,008,000 in the same period of 2022[16]. - Loss per share attributable to owners of the company for continuing operations was HK$0.59 cent, down from HK$2.09 cent in the previous year[16]. - The adjusted loss before tax for the group was HK$18,548,000, compared to a much larger loss of HK$123,573,000 in the previous year[60][65]. - The net loss for the six months ended 30 September 2023 was approximately HK$23.2 million, a significant improvement from a net loss of approximately HK$128.1 million in the same period of 2022[140][142]. Operational Costs - Administrative and other expenses increased to HK$22,730,000 from HK$14,871,000, indicating rising operational costs[11]. - The Group's cash used in operations increased significantly from HK$14,603,000 to HK$45,926,000 year-over-year[27]. - Employee benefit expenses, excluding directors' remuneration, were HK$7,850,000, slightly down from HK$7,874,000, showing a marginal decrease of 0.3%[77]. - The provision for current PRC Land Appreciation Tax (LAT) was HK$4,764,000, compared to HK$2,664,000 in the prior year, marking an increase of approximately 78.3%[84]. Asset and Liability Management - Total non-current assets decreased to HK$739,241,000 as of September 30, 2023, from HK$772,260,000 as of March 31, 2023[20]. - Current assets decreased significantly to HK$686,894,000 from HK$1,643,957,000 over the same period[20]. - Total current liabilities decreased to HK$609,101,000 from HK$1,599,745,000, indicating improved liquidity management[20]. - Net current assets increased to HK$77,793,000 from HK$44,212,000, reflecting a positive shift in short-term financial health[21]. - Non-current liabilities decreased to HK$753,998,000 from HK$807,674,000, showing a reduction in long-term debt obligations[21]. - Equity attributable to owners of the company improved to HK$(70,162,000) from HK$(135,578,000), indicating a recovery in shareholder equity[21]. - The Group's total borrowings as of September 30, 2023 amounted to HK$826,659,000, a decrease from HK$1,147,116,000 as of March 31, 2023[117]. - The gearing ratio of the Group was 13.4 times as of September 30, 2023, a significant decrease from 133.1 times as of March 31, 2023[198]. Investment and Strategic Focus - The Group continues to focus on property development and management services as its primary business strategy moving forward[6]. - The healthcare holiday resort in Shanghai was sold for RMB1,185,000,000 (approximately HK$1,356,519,000), which is a strategic divestment aimed at focusing on core operations[86]. - The Group anticipates challenges in its original property development model in 2024 and plans to upgrade its industrial development strategy focusing on the health industry[176]. - The strategic focus will shift towards investment and operational services in the biopharmaceutical and medical device industry parks starting in 2023[177]. - The Group plans to establish new integrated industrial zones for biomedical and medical devices in the Yangtze River Delta region, replicating the successful experience of Boill e-Pharmaceutical Valley[187]. Cash Flow and Financing - The Group's cash and cash equivalents at the end of the period were approximately HK$24,207,000[30]. - During the same period, cash used in operating activities was HK$46,627,000, compared to cash generated of HK$55,416,000 in the previous year[27]. - The Group generated net cash flows from investing activities of HK$463,496,000, compared to a cash outflow of HK$68,380,000 in the prior year[27]. - A capital contribution of HK$100,000,000 was made by a substantial shareholder through a debt waiver agreement[26]. - The Group's cash and cash equivalents were approximately HK$24,207,000 as of 30 September 2023, indicating a potential liquidity issue[31]. Market and Future Outlook - The company is focusing on enhancing its operational efficiency and exploring new market opportunities to drive future growth[15]. - The Group's operations are segmented into property development and discontinued operations related to the healthcare resort, with the latter no longer reported separately[47]. - Management expects to receive remaining proceeds of RMB79,213,000 (approximately HK$85,014,000) from the disposal of the healthcare holiday resort in Shanghai on time[37]. - The Group plans to cooperate with domestic and foreign biomedical and medical device professional investment funds for strategic investments in enterprises within the zones[189].